Lee J, Chatterjee A, Scarpa M, Bailey C, Niyongere S, Singh P
Cancer Res Commun. 2024; 4(2):431-445.
PMID: 38284896
PMC: 10870818.
DOI: 10.1158/2767-9764.CRC-23-0379.
Long J, Chen X, Shen Y, Lei Y, Mu L, Wang Z
Cell Rep Med. 2023; 4(11):101286.
PMID: 37951217
PMC: 10694671.
DOI: 10.1016/j.xcrm.2023.101286.
Brehova P, Reznickova E, Skach K, Jorda R, Dejmek M, Vojackova V
J Med Chem. 2023; 66(16):11133-11157.
PMID: 37535845
PMC: 10461230.
DOI: 10.1021/acs.jmedchem.3c00575.
Yashar W, Curtiss B, Coleman D, VanCampen J, Kong G, Macaraeg J
Mol Cancer Res. 2023; 21(7):631-647.
PMID: 36976323
PMC: 10330306.
DOI: 10.1158/1541-7786.MCR-22-0745.
Goswami S, Mani R, Nunes J, Chiang C, Zapolnik K, Hu E
Blood. 2021; 139(9):1340-1358.
PMID: 34788382
PMC: 8900275.
DOI: 10.1182/blood.2020010344.
PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition-Dependent GSK-3β-Mediated c-Myc and Pim-1 Proteasomal Degradation.
Scarpa M, Singh P, Bailey C, Lee J, Kapoor S, Lapidus R
Mol Cancer Ther. 2021; 20(4):676-690.
PMID: 33568357
PMC: 8027945.
DOI: 10.1158/1535-7163.MCT-20-0663.
Targeting DNA Repair Pathways in Hematological Malignancies.
Alhmoud J, Mustafa A, Malki M
Int J Mol Sci. 2020; 21(19).
PMID: 33036137
PMC: 7582413.
DOI: 10.3390/ijms21197365.
Homoharringtonine exhibits potent anti-tumor effect and modulates DNA epigenome in acute myeloid leukemia by targeting SP1/TET1/5hmC.
Li C, Dong L, Su R, Bi Y, Qing Y, Deng X
Haematologica. 2019; 105(1):148-160.
PMID: 30975912
PMC: 6939512.
DOI: 10.3324/haematol.2018.208835.
The Myc/Max/Mxd Network Is a Target of Mutated Flt3 Signaling in Hematopoietic Stem Cells in Flt3-ITD-Induced Myeloproliferative Disease.
Basit F, Andersson M, Hultquist A
Stem Cells Int. 2018; 2018:3286949.
PMID: 30420889
PMC: 6215545.
DOI: 10.1155/2018/3286949.
The cell cycle checkpoint inhibitors in the treatment of leukemias.
Ghelli Luserna di Rora A, Iacobucci I, Martinelli G
J Hematol Oncol. 2017; 10(1):77.
PMID: 28356161
PMC: 5371185.
DOI: 10.1186/s13045-017-0443-x.
Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling.
Brunen D, Garcia-Barchino M, Malani D, Jagalur Basheer N, Lieftink C, Beijersbergen R
Oncotarget. 2016; 7(25):37407-37419.
PMID: 27270648
PMC: 5122321.
DOI: 10.18632/oncotarget.9822.
Lineage-specific STAT5 target gene activation in hematopoietic progenitor cells predicts the FLT3(+)-mediated leukemic phenotype.
Muller T, Grundler R, Istvanffy R, Rudelius M, Hennighausen L, Illert A
Leukemia. 2016; 30(8):1725-33.
PMID: 27046463
DOI: 10.1038/leu.2016.72.
TALENs-mediated gene disruption of FLT3 in leukemia cells: Using genome-editing approach for exploring the molecular basis of gene abnormality.
Wang J, Li T, Zhou M, Hu Z, Zhou X, Zhou S
Sci Rep. 2015; 5:18454.
PMID: 26669855
PMC: 4680874.
DOI: 10.1038/srep18454.
MK-2206 induces apoptosis of AML cells and enhances the cytotoxicity of cytarabine.
Lu J, Lin Y, Lai Y, Chen C, Hu C, Tien H
Med Oncol. 2015; 32(7):206.
PMID: 26087957
DOI: 10.1007/s12032-015-0650-7.
c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated Leukemias.
Muvarak N, Kelley S, Robert C, Baer M, Perrotti D, Gambacorti-Passerini C
Mol Cancer Res. 2015; 13(4):699-712.
PMID: 25828893
PMC: 4398615.
DOI: 10.1158/1541-7786.MCR-14-0422.
SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells.
Li L, Osdal T, Ho Y, Chun S, McDonald T, Agarwal P
Cell Stem Cell. 2014; 15(4):431-446.
PMID: 25280219
PMC: 4305398.
DOI: 10.1016/j.stem.2014.08.001.
AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia.
Keeton E, McEachern K, Dillman K, Palakurthi S, Cao Y, Grondine M
Blood. 2013; 123(6):905-13.
PMID: 24363397
PMC: 3916880.
DOI: 10.1182/blood-2013-04-495366.
Pim-1 kinase phosphorylates and stabilizes 130 kDa FLT3 and promotes aberrant STAT5 signaling in acute myeloid leukemia with FLT3 internal tandem duplication.
Natarajan K, Xie Y, Burcu M, Linn D, Qiu Y, Baer M
PLoS One. 2013; 8(9):e74653.
PMID: 24040307
PMC: 3764066.
DOI: 10.1371/journal.pone.0074653.
MicroRNA-16 is down-regulated in mutated FLT3 expressing murine myeloid FDC-P1 cells and interacts with Pim-1.
Kim K, Carroll A, Mashkani B, Cairns M, Small D, Scott R
PLoS One. 2012; 7(9):e44546.
PMID: 22970245
PMC: 3435263.
DOI: 10.1371/journal.pone.0044546.
FLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasm.
Chu S, Heiser D, Li L, Kaplan I, Collector M, Huso D
Cell Stem Cell. 2012; 11(3):346-58.
PMID: 22958930
PMC: 3725984.
DOI: 10.1016/j.stem.2012.05.027.